David Hough
About
David Hough is a scholar working on Psychiatry and Mental health, Pharmacology and Neurology.
According to data from OpenAlex, David Hough has authored 69 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Psychiatry and Mental health, 26 papers in Pharmacology and 14 papers in Neurology. Recurrent topics in David Hough's work include Schizophrenia research and treatment (42 papers), Treatment of Major Depression (26 papers) and Pharmaceutical studies and practices (12 papers). David Hough is often cited by papers focused on Schizophrenia research and treatment (42 papers), Treatment of Major Depression (26 papers) and Pharmaceutical studies and practices (12 papers). David Hough collaborates with scholars based in United States, Belgium and France. David Hough's co-authors include Pilar Lim, Srihari Gopal, Rosanne Lane, Mariëlle Eerdekens, Jaskaran Singh, Isaac Nuamah, Wayne C. Drevets, Husseini K. Manji, Bart Remmerie and Gerard Sanacora and has published in prestigious journals such as American Journal of Psychiatry, Biological Psychiatry and Journal of the American Academy of Child & Adolescent Psychiatry.
In The Last Decade
David Hough
68 papers receiving 4.1k citations
Hit Papers
Peers
David Hough
Pilar Lim United States
Anthony J. Rothschild United States
Myrto Samara Germany
Antony Loebel United States
Larry Alphs United States
Rosanne Lane United States
Robert Lasser United States
Gerd Laux Germany
T.M. Sanger United States
Ronald N. Marcus United States
Citations per year, relative to David Hough David Hough (= 1×)
peers
Pilar Lim
Countries citing papers authored by David Hough
Since
Specialization
Citations
This map shows the geographic impact of David Hough's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Hough with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Hough more than expected).
Fields of papers citing papers by David Hough
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by David Hough. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Hough. The network helps show where David Hough may publish in the future.
Co-authorship network of co-authors of David Hough
This figure shows the co-authorship network connecting the top 25 collaborators of David Hough. A scholar is included among the top collaborators of David Hough based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Hough. David Hough is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Ochs-Ross, Rachel, Ewa Wajs, Ella Daly, et al.. (2021). Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study. American Journal of Geriatric Psychiatry. 30(5). 541–556.
2.
Fu, Dong‐Jing, Dawn F. Ionescu, Xiang Li, et al.. (2020). Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent. The Journal of Clinical Psychiatry. 81(3).
3.
Pandina, Gahan, Isaac Nuamah, Timothy Petersen, et al.. (2020). Cognitive functioning in adolescents with schizophrenia treated with paliperidone extended-release: 6-Month exploratory analysis from an open-label, single-arm safety study. Schizophrenia Research Cognition. 20. 100173–100173.
4.
Morrison, Robert M., Jaskaran Singh, Ella Daly, et al.. (2019). Effect of esketamine nasal spray on cognition in patients with treatment-resistant depression: results from five phase-3 studies. European Neuropsychopharmacology. 29.
5.
Popova, Vanina, Ella Daly, Madhukar H. Trivedi, et al.. (2019). Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. American Journal of Psychiatry. 176(6). 428–438.
6.
Turkoz, Ibrahim, Wing Chow, Larry Alphs, et al.. (2018). Interpretation of Change In Patient-Reported Outcomes in Treatment-Resistant Depression. Value in Health. 21. S187–S187.
7.
Mathews, Maju, Huiling Pei, Adam Savitz, et al.. (2018). Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis. Clinical Drug Investigation. 38(8). 695–702.
8.
Gopal, Srihari, Rosanne Lane, Isaac Nuamah, et al.. (2017). Evaluation of Potentially Prolactin-Related Adverse Events and Sexual Maturation in Adolescents with Schizophrenia Treated with Paliperidone Extended-Release (ER) for 2 Years: A Post Hoc Analysis of an Open-Label Multicenter Study. CNS Drugs. 31(9). 797–808.
9.
Savitz, Adam, Haiyan Xu, Srihari Gopal, et al.. (2017). Paliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia. International Clinical Psychopharmacology. 32(6). 329–336.
10.
Savitz, Adam, Haiyan Xu, Srihari Gopal, et al.. (2016). Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study. The International Journal of Neuropsychopharmacology. 19(7). pyw018–pyw018.
11.
Savitz, Adam, Rosanne Lane, Isaac Nuamah, et al.. (2015). Long-Term Safety of Paliperidone Extended Release in Adolescents with Schizophrenia: An Open-Label, Flexible Dose Study. Journal of Child and Adolescent Psychopharmacology. 25(7). 548–557.
12.
Savitz, Adam, Rosanne Lane, Isaac Nuamah, Srihari Gopal, & David Hough. (2014). Efficacy and Safety of Paliperidone Extended Release in Adolescents With Schizophrenia: A Randomized, Double-Blind Study. Journal of the American Academy of Child & Adolescent Psychiatry. 54(2). 126–137.e1.
13.
Kent, Justine, David Hough, Jaskaran Singh, Keith Karcher, & Gahan Pandina. (2013). An Open-Label Extension Study of the Safety and Efficacy of Risperidone in Children and Adolescents with Autistic Disorder. Journal of Child and Adolescent Psychopharmacology. 23(10). 676–686.
14.
Kent, Justine, Stuart Kushner, Xiaoping Ning, et al.. (2012). Risperidone Dosing in Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Controlled Study. Journal of Autism and Developmental Disorders. 43(8). 1773–1783.
15.
Fleischhacker, W. Wolfgang, Srihari Gopal, Rosanne Lane, et al.. (2011). A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. The International Journal of Neuropsychopharmacology. 15(1). 107–118.
16.
Nasrallah, Henry A., Srihari Gopal, Cristiana Gassmann-Mayer, et al.. (2010). A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia. Neuropsychopharmacology. 35(10). 2072–2082.
17.
Gopal, Srihari, David Hough, Haiyan Xu, et al.. (2010). Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. International Clinical Psychopharmacology. 25(5). 247–256.
18.
Berwaerts, Joris, Rosanne Lane, Isaac Nuamah, et al.. (2010). Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: A randomized, placebo-controlled study. Journal of Affective Disorders. 129(1-3). 252–260.
19.
Kramer, Michelle, Robert E. Litman, David Hough, et al.. (2009). Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. The International Journal of Neuropsychopharmacology. 13(5). 635–647.
20.
Hough, David, Srihari Gopal, Ujjwala Vijapurkar, et al.. (2009). Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study. Schizophrenia Research. 116(2-3). 107–117.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Pilar Lim Breakdown of academic impact, for papers by Anthony J. Rothschild Breakdown of academic impact, for papers by Myrto Samara Breakdown of academic impact, for papers by Antony Loebel Breakdown of academic impact, for papers by Larry Alphs Breakdown of academic impact, for papers by Rosanne Lane Breakdown of academic impact, for papers by Robert Lasser Breakdown of academic impact, for papers by Gerd Laux Breakdown of academic impact, for papers by T.M. Sanger Breakdown of academic impact, for papers by Ronald N. Marcus